Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;18(3):139-147.
doi: 10.1038/nrc.2017.117. Epub 2018 Jan 12.

Impact of oncogenic pathways on evasion of antitumour immune responses

Stefani Spranger  1 , Thomas F Gajewski  2   3
Affiliations
Review

Impact of oncogenic pathways on evasion of antitumour immune responses

Stefani Spranger et al. Nat Rev Cancer. 2018 Mar.

Abstract

Immunotherapeutic interventions are showing effectiveness across a wide range of cancer types, but only a subset of patients shows clinical response to therapy. Responsiveness to checkpoint blockade immunotherapy is favoured by the presence of a local, CD8+ T cell-based immune response within the tumour microenvironment. As molecular analyses of tumours containing or lacking a productive CD8+ T cell infiltrate are being pursued, increasing evidence is indicating that activation of oncogenic pathways in tumour cells can impair induction or execution of a local antitumour immune response. This Review summarizes our current knowledge of the influence of oncogenic effects on evasion of antitumour immunity.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare no competing financial interests.

Figures

Figure 1 |
Figure 1 |. Induction phase of a productive antitumour immune response.
From left to right: tumour cells produce CC-chemokine ligand 4 (CCL4), inducing the recruitment of basic leucine zipper transcriptional factor ATF-like 3 lineage dendritic cells (BATF3 DCs). BATF3 DCs sense the tumour and produce interferon α (IFNα) and IFNβ while migrating to the tumour-draining lymph node. Here, activated BATF3 DCs prime antigen-specific T cells, which subsequently home back into the tumour under the influence of CXC-chemokine ligand 9 (CXCL9) and CXCL10. Other chemokines (for example, CCL2) recruit other effector cells such as natural killer (NK) cells.
Figure 2 |
Figure 2 |. Impact of oncogenic signalling on immune inhibitory pathways and cell populations.
β-catenin: immune exclusion mediated by activation of the WNT–β-catenin pathway occurs when expression of CC-chemokine ligand 4 (CCL4) is inhibited and thus basic leucine zipper transcriptional factor ATF-like 3 lineage dendritic cells (BATF3 DCs) are no longer recruited into the tumour microenvironment. Consequently, owing to a lack of CXC-chemokine ligand 10 (CXCL10) production by BATF3 DCs, no T cell priming occurs, and effector T cells are not recruited into the tumour. MYC: activation of MYC signalling enhances the expression of leukocyte surface antigen CD47 and programmed cell death 1 ligand 1 (PDL1) on tumour cells through transcriptional regulation. Expression of these immune inhibitory molecules interferes with antigen uptake by antigen-presenting cells (APCs) via engagement with signal regulator protein-α (SIRPα) and inhibits T cell function via PD1 engagement, respectively. LKB1: loss of liver kinase B1 (LKB1) signalling within tumour cells results in increased expression of various cytokines, including interleukin-6 (IL-6), IL-33 and CXCL7. IL-6 mediates recruitment of neutrophils into the tumour microenvironment, an immunosuppressive cell type that contributes to reduced T cell infiltration and promotes T cell dysfunction. LKB1 mutations can also lead to activation of MYC signalling within the same tumour cells, providing potential crosstalk between pathways. PTEN: loss of PTEN protein function and thereby activation of PI3K inhibits lipidation of the autophagosome protein LC3 and autophagy in tumour cells, a process that can diminish T cell priming and also mediate resistance to T cell-mediated apoptosis. TP53: effector T cell exclusion from the tumour can occur owing to inactivating TP53 mutations, which results in reduced chemokine production by tumour cells. In particular, TP53-mutated tumour cells lack production of key chemokines required for the recruitment of natural killer (NK) cells and T cells, which is required for NK cell recruitment into the tumour microenvironment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 363, 711–723 (2010). - PMC - PubMed
    1. Topalian SL et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 366, 2443–2454 (2012). - PMC - PubMed
    1. Larkin J et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med 373, 23–34 (2015). - PMC - PubMed
    1. Le DT et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017). - PMC - PubMed

    1. Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 568–571 (2014).

      This work provides proof that response to checkpoint blockade therapy (anti-PD1) is associated with the presence of T cells in the tumour microenvironment (TME) (T cell-inflamed phenotype).

Publication types

MeSH terms

Substances